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XAP2 is member of a protein family sharing the TPR protein interaction motif. It displays close
homology to the immunophilins FKBP51 and FKBP52 that act via the Hsp90 folding machinery to
regulate the glucocorticoid receptor (GR). We show that XAP2 inhibits GR by reducing its responsive-
ness to hormone in transcriptional activation. The effect of XAP2 on GR requires its interaction with
Hsp90 through the TPR motif. The PPIase-like region turned out to be enzymatically inactive. Thus,
PPIase activity is not essential for the action of XAP2 on GR, similarly to FKBP51 and FKBP52.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Corticosteroids show a broad variety of physiological functions
[1]. Their effects are mainly mediated via two members of the nu-
clear receptor family [2], the mineralocorticoid receptor (MR) and
the glucocorticoid receptor (GR). It is generally accepted that GR
resides predominantly in the cytoplasm in the absence of hormone
as part of a large chaperone heterocomplex which contains
amongst others an Hsp90 dimer, p23 and one member of the
TPR-(tetratricopeptide repeat) protein family such as FKBP51 or
FKBP52 [3,4]. Upon ligand binding, GR dissociates from the hetero-
complex and translocates into the nucleus where it regulates tran-
scription either by binding to its cognate DNA elements or by
interacting with other transcription factors [5].
Chaperones regulate GR function at least at three distinct levels.
The folding of GR in the cytoplasm by molecular chaperones has
been intensely investigated [4,6], but evidence has also been pro-
vided that they are involved in nuclear translocation of GR [7–9]
and in disassembly of its transcriptional complexes [10]. The
highly homologues immunophilins FKBP51 and FKBP52 display
differential effects on GR folding and nuclear translocation [7,11].
FKBP51 has recently attracted particular interest, because it waschemical Societies. Published by E
n).found to be genetically associated with various stress-related dis-
orders and phenotypes [12–17]. This is intriguing, because the role
of GR in a range of stress-related diseases is well documented [18].
The hepatitis virus B X-associated protein 2 (XAP2) is a 37 kDa-
protein with wide distribution in human tissues that was initially
identiﬁed as an interacting partner of the hepatitis virus B X-pro-
tein [19]. It is also known as AhR (arylhydrocarbon receptor)-inter-
acting protein (AIP), AhR-associated protein 9 (ARA9) or FKBP23.
XAP2 contains three TPR-domains and a PPIase-like domain in
the N-terminus and shows homology to FKBP51 and FKBP52
[20,21]. In contrast to these immunophilins, XAP2 does not bind
to FK506 [11]. Nevertheless, the enzymatic activity of its PPIase-
like domain is considered unclear at present [22]. XAP2 has been
described to act on AhR in concert with Hsp90 in yeast as well as
in mammalian cells [20,23–26]. XAP2 was reported to reduce ubiq-
uitination of the receptor and to regulate its subcellular distribu-
tion, albeit there is some controversy about the exact details
[27–29]. More recently, it has been shown that XAP2 interacts with
and is required for, another member of the family of the b activa-
tion of thyroid hormone receptor 1 nuclear receptors [30].
Because of its homology to established GR regulators, we
tested potential effects of XAP2 on GR in mammalian cells. We
show that XAP2 inhibits GR transcriptional activity and inﬂuences
intracellular distribution of the receptor in a time-dependent man-
ner. Moreover, we show that the PPIase-like domain of XAP2 dis-
plays no enzymatic activity. This is in line with the effects of
FKBP51 and FKBP52 on GR, which are independent of their PPIase
activity.lsevier B.V. All rights reserved.
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2.1. Cell culture, transfection, and reporter gene assays
Cultivation and transfection of human neuroblastoma SK-N-MC
cells, HEK cells and HeLa cells were as described previously [7].
Two days before transfection, cells were seeded in steroid-free
medium.
Transfection was by ExGen (Fermentas) according to the manu-
facturer’s instructions. Unless indicated otherwise, about 50,000
cells were transfected with 40 ng MTV-Luc-, 5–30 ng pCMV-Gaus-
sia-luciferase and 25 ng PRK7-GR-plasmid. The overall amount of
transfected plasmids was equaled for each condition by supple-
menting ‘‘empty” expression vector. After transfection (0–8 h),
cells were seeded in steroid-free medium containing either hor-
mone or the respective solvent for 16 h.
Fireﬂy luciferase and Gaussia luciferase assays were as de-
scribed [31] and as recommended by the manufacturer (PJK
GmbH).
2.2. Plasmids
MTVLuc-, FLAG-GR, GFP-GR-, FKBP51 WT- and FKBP51 TPR-
MUT-plasmids have been described previously [7].
XAP2 WT-plasmids were a kind gift of I. Pongratz (Karolinska
Institute, Stockholm, Sweden). The TPR-mutation in FLAG-XAP2
(K266A, R271A) within the TPR-domain by alanines was intro-
duced by using the QuickChange Site-Directed Mutagenis Kit
(Stratagene).Fig. 1. XAP2 inhibits the transcriptional activity of GR. (A) SK-N-MC cells were
transfected with the reporter plasmid MTV-Luc, the Gaussia luciferase control
plasmid, a GR expressing plasmid and the XAP2 expression plasmids at increasing
amounts. Cells were cultivated over night in the presence of 10 nM cortisol or the2.3. Immunoprecipitation and Western blot
HEK cells were transfected by electroporation with 10 lg of a
plasmid expressing a FLAG-tagged form of XAP2WT, XAP2TPRMUT,
or FKBP51WT, or the empty expression vector in the control condi-
tion. For the competition experiment (Fig. 2C) 1–2 lg of XAP2FLAG
plasmid were transfected along with increasing amounts of
FKBP52, or cloning vector to keep the overall amount of plasmid
constant. Cell lysis, immunoprecipitation and immunoblots were
as described previously [7].
2.4. Fluorescence analysis
HeLa cell cultivation, transfection with GFP-GR together with
either XAP2WT or control vector, and evaluation of the results
was as described previously [7]. Between 167 and 193 cells were
evaluated for each experimental condition.solvent ethanol and then harvested for determination of ﬁreﬂy luciferase and
Gaussia luciferase activities. Data are presented as relative stimulation ±S.E. of 7
independent experiments. Lower panel: Western control of XAP2 expression in
representative lysates used in A. (B) Western blot control of GR expression in
representative lysates used in A. (C) The inhibitory action of XAP2 on GR depends on
the concentration of cortisol.2.4.1. XAP2 expression and puriﬁcation
The PPIase-like domain of Xap2 comprising amino acids 1–121
(XAPfrag121) was cloned into the pMAL cRI vector (New England
Biolabs) to create a soluble XAPfrag121-MBP fusion protein. This
protein was then expressed in Escherichia coli (pBL3Lys, Invitro-
gen) cultivated in LB media with 0.3 mM isopropyl-ß-D-C-thioga-
lactopyranoside (IPTG) for 2 h at 30 C. Puriﬁcation was
performed over an amylose resin column (New England Biolabs)
as described [32]. In some fractions MBP was cleaved off by Factor
Xa (New England Biolabs). Protein concentrations were deter-
mined with the Bradford assay (BCA kit, Pierce) and estimated
in parallel by comparison with a marker protein in a Coomassie
gel. As positive control, FKBP52 and FKBP12 were cloned into a
pProExHTa vector, expressed in E. coli and puriﬁed on a Ni-NTA
agarose column according to the manufacturer’s recommenda-
tions (Qiagen).2.4.1.1. Active site titration. The binding of XAPfrag121 to the
immunophilin ligand rapamycin was analysed in a ﬂuorescence
polarization assay [33]. Fluorescent ligand (Rap-Fl, Kozany et al.,
[43]) was used in three different concentrations (3, 12 and
48 nM) in assay buffer (20 mM HEPES, 0.01% Triton X-100, pH
8.0) to measure titration curves for FKBP52 as a positive control.
A concentration of 48 nM of the ﬂuorescent ligand was used for
the titration curve with XAPfrag121 (n = 2). After incubation at
room temperature for 30 min the ﬂuorescence polarization was
measured in a Tecan reader (Genios Pro). The binding curves were
analysed using Sigma Plot9. For the analysis of Kd values, the data
Fig. 2. The activity of XAP2 on GR is Hsp90-dependent. (A) Plasmids coding for a FLAG-tagged form of XAP2WT, XAP2MUT (K266A, R271A), and FKBP51 or empty vector as
controls were transfected into HEK cells. Interaction with Hsp90 was probed in lysates obtained the next day. (B) Reporter gene assay as in Fig. 1A to test the inﬂuence of the
TPR-mutated XAP2 on GR. Lower panel, expression control. (C) Co-immunprecipitation like in (A) to probe the Hsp90 interaction of XAP2 in the absence or presence of
increasing amounts of FKBP52 as competitor. (D) Reporter gene assay as in Fig. 1A to test the ability of FKBP52 to counteract the inhibitory action of XAP2 on GR. Amounts of
(co-)transfected plasmids are indicated. *p > 0.05, ***p < 0.001.
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[L]t]{[([R]t + [L]t + Kd)/2]
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð½Rt þ ½Lt þ KdÞ=2
 2  ½Lt ½Rt
n or
} + Amin.
(Amax: maximal anisotropy value, Amin: minimal anisotropy value,
Kd: dissociation constant of the used ligand, [L]t: total concentra-
tion of used ligand, [R]t: total concentration of titrated protein
receptor.)
2.4.2. PPIase assay
The PPIase activity was assessed by a spectrophotometric chy-
motrypsin-coupled enzymatic assay as described [35]. In this assay
the peptide substrate Suc-ALPF-pNitroanilide is reversibly cis–
trans isomerised by a PPIase. In a second step the trans-isomer is
hydrolysed by chymotrypsin, which results in release of pNitroani-
lide and a consecutive increase in absorbance at 390 nM. The C in a
buffer containing 50 mM HEPES and 100 mM NaCl assay was con-
ducted at 4 (pH 8.0). The peptide substrate was dissolved at 4 mM
in a solution of 470 mM LiCl in dry triﬂuoroethanol and stored un-
der argon to exclude water vapor. Substrate was added at a ﬁnal
concentration of 100 lM immediately before measurements in a
spectrophotometer (Beckmann DU530). Absorbance was then
monitored until the reaction was complete (2–10 min). Curves
were analysed using Sigma Plot9 and ﬁtted with a three parameter
ﬁt for an exponential rise to a maximum (y = y0 + a(1ebx)).
To avoid interference by a potential chymotrypsin sensitivity of
the proteins, the order of addition of the assay components waschanged. The peptide substrate in dry triﬂuoroethanol/470 mM
LiCl was added to XAP2, FKBP52 or no protein control in the
absence of chymotrypsin at the concentrations described
above. After 3 min incubation at 4 C, chymotrypsin was added
and the progress curves were ﬁtted as above to determine the
trans conﬁguration at the start of the chymotrypsin reaction
(pNA burst).3. Results
3.1. XAP2 inhibits GR-dependent transcription in mammalian cells
To investigate the effect of XAP2 on the transcriptional activity
of GR, we used a GR-responsive reporter assay [7]. In two different
cell lines, the neuroblastoma cell line SK-N-MC and HEK cells, we
observed impaired GR-mediated transcription the more XAP2
was ectopically expressed (Fig. 1A). As over-expression of XAP2
did not lead to a decrease of GR-protein levels in our test system
(Fig. 1B), we could exclude receptor degradation as a possible
mechanism of the observed XAP2-dependent inhibitory effect on
GR.
Moreover, XAP2 inhibited GR less efﬁciently at higher concen-
trations of hormone (Fig. 1C). This suggests that the inhibitory
effect of XAP2 on GR activity is at least partially due to a reduction
in ligand-binding afﬁnity of the receptor.
Fig. 3. XAP2 delays nuclear translocation of GR. HeLa cells were transfected with
0.25 lg of a plasmid encoding GR-GFP together with 0.75 lg of either vector control
or wtXAP2 plasmid. After one day, cells were exposed to 10 nM cortisol, ﬁxed after
the indicated times and the nucleus/cytosol distributions were scored for each time
point in two independent experiments.
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Hsp90-dependence has been demonstrated for the FKBP51-in-
duced inhibition of GR [3]. For the interaction of XAP2 with
Hsp90, the integrity of the TPR domain is essential [8,23,24]. To
create an XAP2-protein that lacks Hsp90-interaction, we replaced
the positively charged amino acids lysine (266) and arginine
(271) within the TPR-domain by alanines, following a similar strat-
egy that successfully disabled Hsp90 interaction of other TPR pro-
teins such as FKBP5 and PP5 [7,36,37]. We veriﬁed that the TPR-
mutated XAP2 lost the ability to interact with Hsp90 by co-immu-
noprecipitation (Fig. 2A). This mutant did also not inhibit GR-
dependent transcriptional activity at protein levels that, in the case
of wtXAP2, were sufﬁcient to reduce GR activity (Fig. 2B). At the
highest amount of expression plasmid used, some effect on GR
was observed, which may be due to residual Hsp90 binding of
the mutated XAP2. A similar result was observed with a plasmid
encoding for TPR-mutated FKBP51 (data not shown).
To show the competition between other Hsp90 binding TPR-
cofactors and XAP2 more directly, we expressed XAP2FLAG to-
gether with increasing amounts of FKBP52 in HEK cells. Co-precip-
itation of XAP2 shows comparable amounts of XAP2 precipitation
throughout the different conditions. Increasing amounts of co-ex-
pressed FKBP52 resulted in decreasing amounts of Hsp90 co-pre-
cipitated with XAP2 (Fig. 2C).
To test the consequences of this competition on the transcrip-
tional activity of GR, we co-expressed XAP2 together with increas-
ing amounts of FKBP52 in a reporter gene assay. We observed that
FKBP52 was indeed able to rescue GR activity, which had been
diminished by XAP2 (Fig. 2D). Co-expression of FKBP52 in the ab-
sence of XAP2 did not inﬂuence GR activity, as described previ-
ously [7].
Thus, XAP2 inﬂuences GR via the Hsp90 heterocomplex.
3.3. XAP2 delays nuclear accumulation of hormone-bound GR
An inhibitory inﬂuence of XAP2 on the subcellular distribution
of AhR in the presence as well as in the absence of ligand has been
reported [27,29]. Moreover, we have found that FKBP51 signiﬁ-
cantly reduces nuclear translocation of GR and disrupts interaction
of the GR heterocomplex with the motor protein dynein [7].
To investigate a possible effect of XAP2 on nuclear accumulation
of GR, we followed the subcellular localisation of a GFP-tagged GR-
protein with or without co-transfected XAP2 in HeLa cells after
incubation with 10 nM cortisol for up to 60 min. The distribution
of GR between cytosol and nucleus was monitored under a ﬂuores-
cent microscope. For each experimental condition, >100 cells were
classiﬁed by a blinded and independent scientist. Cells were scored
from 1 (exclusively cytoplasmic detection) to 5 (exclusively nuclear
detection) as described in the literature [27]. In the absence of ecto-
pic XAP2, we observed the expected hormone dependent nuclear
accumulation of the receptor (Fig. 3). When co-expressing XAP2,
we detected no signiﬁcant difference in GR-subcellular localisation
in the absence of ligand (Fig. 3). After addition of hormone, we ob-
served a time-dependent reduction of the nuclear accumulation of
GR in cells with XAP2 with a maximum at 20–40 min. After 60 min,
XAP2 had no inﬂuence on the subcellular localisation of GR. Thus,
GR accumulation in the nucleus is not blocked, but rather delayed.
3.4. The PPIase-like domain of XAP2 does not bind to rapamycin and
shows no PPIase activity
So far, it has been unclear whether the PPIase-like domain of
XAP2 is enzymatically active [22,23]. There are several immunophi-
lin ligands known, which bind to the PPIase domain of the immuno-
philins and inhibit PPIase activity. Amongst the most commonlyused ones are FK506 and rapamycin, and FK506 has already been
found not to bind Xap2 [23]. Using a ﬂuorescence polarization as-
say, we show here that rapamycin does not bind to Xap2 either
(Fig. 4A). FKBP52 was used as a positive control for the efﬁcient
binding of the ﬂuorescent dye-tagged rapamycin (Fig. 4A). At a con-
centration of 3 nMRap-Fl, the approximate Kd of rapamycin binding
to FKBP52 was calculated as 2.8 nM, which is in the range of previ-
ously published data ([38]: Kd = 6.12 nM; [39]: Kd = 1.4 nM).
To measure the PPIase activity, we employed a chymotrypsin-
coupled enzymatic assay. As shown in Fig. 4B, FKBP12 displayed
clear catalytic activity, while the isomerization rates observed for
the Xap2 PPIase-like domain did not differ from the uncatalysed
thermal isomerization rate of the control. Whether the Xap2 frag-
ment was still fused to MBP, or had been cleaved off by factor Xa,
made no detectable difference. To rule out the possibility that MBP
or factor Xa have a general inhibitory effect on PPIase activity, we
also added FKBP12 as a positive control, but its PPIase activity was
not affected.
It was possible that XAP2 shows no activity, because its PPIase
domain was degraded by the protease chymotrypsin during the as-
say. Since we could not exclude this possibility by gel electropho-
resis (data not shown), we performed a discontinuous PPIase assay.
The FKBP-catalyzed or background cis–trans re-equilibration was
induced by a rapid shift of the substrate from dry triﬂuoroetha-
nol/LiCl to aqueous buffer in the absence of chymotrypsin. The
amount of formed trans-substrate was determined after deﬁned
time points by the addition of chymotrypsin and ﬁtting of the
pNA-generation progress curve (displayed for the additions after
3 min in Fig. 4C). The percentage of trans-substrate increased from
an initial 70% trans substrate to the expected equilibrium of 90%
trans within 10 min (data not shown). Importantly, at intermediate
time points, FKBP52-containing samples clearly equilibrated faster
than XAP2-containing samples, which were undistinguishable
from background samples (Fig. 4D).
Thus, the actions of XAP2 on GR, as well as the other docu-
mented actions of XAP2, are independent of peptidyl prolyl
isomerisation.
4. Discussion
The discovery of TPR proteins like FKBP52, FKBP51, CHIP and
PP5 as important regulators of GR raises the question of whether
other TPR proteins would also have the potential to inﬂuence GR.
We show here that XAP2 speciﬁcally reduces GR’s transcriptional
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data suggest that a reduction in ligand-binding afﬁnity, and maybe
to some degree also a delay in nuclear accumulation of GR, is in-
volved in the mechanism of this inhibitory effect. XAP2 left the
protein levels of GR unchanged.
XAP2 showed no effect on GR in yeast in an earlier study [23].
This is congruent with our discovery in mammalian cells, because
in contrast to mammalian cells, GR activity is suboptimal in yeast,
possibly due to the lack of some TPR cofactors. As a consequence,
FKBP51, which inhibits GR in mammalian cells, has no effect in
yeast [7,11].
We show here that, unlike the FKBPs and despite its homology
to the large FKBPs, Xap2 does not bind to rapamycin and displays
no PPIase activity. Initially, it has been proposed that the PPIase
activity is important for the regulatory effect of FKBP52 in GR sig-
nalling [7,11]. However, it has been shown more recently that a
speciﬁc structure of the PPIase domain is the relevant feature,
rather than the enzymatic activity itself [40]. In addition, the PPI-
ase activity of FKBP51 is also not required for the inhibitory ac-
tion of this immunophilin on GR in mammalian cells [7]. Thus,
the role, if any, of peptidyl prolyl isomerisation in the regulatory
function of the steroid receptors by the FKBPs is not yet clear. As
for FKBP51, no speciﬁc biochemical function is known for XAP2
that is essential for the inhibitory effect on GR. It is possible that
these two factors simply act as competitors that at certain
expression levels expel crucial factors from the TPR acceptor site
of Hsp90. XAP2 may not be the most prominent regulator of GR,
but could become relevant for GR under certain physiological
conditions. For example, XAP2 is widely expressed, but varies
greatly between tissues, and activation and nuclear transloca-
tion of AhR could disengage XAP2 which could then affect GR
[41].
Like FKBP51, XAP2 also delays nuclear translocation of GR upon
hormone stimulation, but only to a small degree. Wemeasured this
effect at sub-saturating levels of cortisol. Since the effect was only
small short-term and disappeared after about 1 h, it is less likely to
be explained by an effect of XAP2 on hormone binding afﬁnity. Our
assay conditions were not sensitive enough to detect an effect, if
any, of XAP2 on GR-dependent transcription after very short expo-
sure times (data not shown). Therefore, the physiological relevance
of the small delay in nuclear translocation is unclear.
After demonstration of a regulatory role of XAP2 for AhR [24,42]
and the hormone receptor TRb1 [30], our study adds with GR an-
other nuclear receptor affected by XAP2. Whether XAP2 has the
ability to act on other members of the nuclear receptor family, re-
mains to be determined.Fig. 4. The PPIase-like domain of XAP2 does not bind to rapamycin and is
enzymatically inactive. (A) The PPIase-like domain of XAP2 (fragment 121) was
expressed as a soluble MBP fusion protein in E. coli and then afﬁnity puriﬁed over an
amylose column. Binding of a ﬂuorescent ligand (Rap-Fl) to the target protein was
analyzed by a ﬂuorescence polarization assay. FKBP52 was used as a control with
different concentrations (3, 12, 48 nM) of Rap-Fl. The experiment with the XAP2-
fragment was conducted in duplicate at 48 nM of Rap-Fl. (B) PPIase activity of
puriﬁed XAP2 (fragments 121) was assessed in a chymotrypsin-coupled enzymatic
assay. The release of pNitroanilide from the trans form of the substrate was
monitored in a spectrophotometer with time. FKBP12 was added to the protein
solution as a positive control. (C) Isomerisation reactions were started in the
absence of chymotrypsin, which was added 3 min later to record the % trans
conformation. (D) Quantiﬁcation of the % trans conformation after 3 min in the
absence of chymotrypsin. Mean values ± mean errors of 3 independent experiments
are displayed.
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